Loading
NASDAQBasic MaterialsOther Precious Metals
Latest quote
$5.65
−$0.18 · -3.09%
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
Regular session
$5.65
−$0.18 · -3.09%
Regular session · ET · Market data may be delayed.
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
Day range
Current $5.65
52-week range
Current $5.65
Regular session · ET · Market data may be delayed.
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
Day range
Current $5.65
52-week range
Current $5.65
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 634.19K USD | — | — | — | — |
| Selling, general, and administrative | 6.51M USD | 5.54M USD | 631.32K USD | 533.99K USD | 1.11M USD |
| Operating expenses | 7.15M USD | 5.54M USD | 631.32K USD | 657.02K USD | 1.11M USD |
| Interest income | — | — | — | 1.28M USD | — |
| Interest expense | 2.31M USD | 356.6K USD | 76.21K USD | — | — |
| Depreciation and amortization | — | — | — | — | 1.11M USD |
| Operating income | −7.15M USD | −5.54M USD | −631.32K USD | −657.02K USD | −1.11M USD |
| Net income | −10.55M USD | −6.15M USD | −707.46K USD | 1.23M USD | −1.11M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 24, 2026 | 1:50 | — | — |
Effective Aug 24, 2026
1:50
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
